Home MarketAarti Drugs Ltd.

Aarti Drugs Ltd. Stock Info: As on 2017-09-20 11:09:58

Nse

537.75

1.55(0.29%)
Change%
52 Week Range
447.80
24.00
686.45
7.00
Open532.15
Day's Range428.96 - 643.44
Value Traded (in ₹ Cr.) 0.20

Bse

534.50

-2.50(-0.47%)
Change %
52 Week Range
456.25
24.00
684.00
7.00
Open531.50
Day's Range429.60 - 644.40
Value Traded (in ₹ Cr.) 0.00

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 14,952,106.00 62.67%
Mutual Funds/UTI 877,023.00 3.68%
FII 175,254.00 0.73%
Employee 0.00 0.00%
Public 6,780,296.00 28.42%
Government 0.00 0.00%
Others 882,684.00 3.70%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 1.02
Basic EPS (Rs.) 27.37
Cash EPS 42.06
BVPerShare Excl 144.66
Operating Revenue 444.11
PBDITPerShare 70.90
Dividend 6.75
NPPerShare 27.37
Current Ratio 1.14
Quick Ratio 0.78
PriceToBV 3.14
Earnings 0.06
PBDIT Margin 15.96
PBT Margin 8.63
NP Margin 6.16
Return On Assets 6.28
Retention Ratios 75.33
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,075.50
Total Expenses 982.66
EBITDA 171.70
PBT 92.84
PAT 66.29
Net Income 66.29
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 554.18
Total Expenses 486.08
EBITDA 50.03
PBT 45.77
PAT 33.72
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Company Curr Price Prev. Close Change% W's Low/High

Abbott India Ltd.

4145.05 4172.75 -0.66
40014206.05

Ajanta Pharma Ltd.

1201 1197.6 0.28
11821251.2

Albert David Ltd.

293.95 291 1.01
282.5307.35

Alembic Ltd.

38.65 38.75 -0.26
38.1540

Alembic Pharmaceuticals Ltd.

481.6 482.95 -0.28
469.85515.85

Alkem Laboratories Ltd.

1769.1 1777.35 -0.46
17341819

Alpa Laboratories Ltd.

29.2 28.45 2.64
27.8530.35
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

114 115.1 -0.96
109.5127

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4160 4171.4 -0.27
40354202.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3

Advik Laboratories Ltd.

4.72 4.52 4.42
4.24.86
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 125.27
Cash from investing activities -87.40
Cash from financing activities -36.79
Net change in cash 1.07

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
DSP BlackRock Micro-Cap Fund 0.78%

Infosys Finacle partners with Niki.ai

Infosys Finacle part of EdgeVerve Systems, a wholly-owned subsidiary of Infosys has partnered with Niki.ai, a FinTech start-up to offer chat based commerce to banking customers. With this partnership, Finacle solution suite will be available with Niki.ai's chat-based virtual assistant-Niki. This offering will enable banks to offer its customers a virtual banking assistant for shopping products and services. The joint solution from Finacle and Niki.ai will provide a smart-purchasing chatbot by leveraging natural language processing and machine learning to converse with customers and perform online transactions. The bot will comprehend natural speech text in the context of the customer and will deliver personalized suggestions. The solution will provide banks an opportunity to initiate two-way automated intelligent conversations with customers. Meanwhile, shares of the company closed trading at Rs 911.30 apiece, up 0.31 per cent from the previous close on BSE.

19-09-2017 16:56

Shriram Transport Finance raises Rs 50 cr via bonds

Shriram Transport Finance Company Ltd said it has raised Rs 50 crore by issuing Secured Redeemable Rated Listed Non-Convertible Debenture on private placement basis. “The Allotment Committee - NCDs of the Company in its meeting held today, approved and allotted 500 Secured Redeemable Rated Listed Non-Convertible Debenture of face value of Rs.10,00,000/- (Rupees Ten Lakh only) each, aggregating to Rs. 50 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds with a tenor of 3 years, 11 months and 29 days, carries a coupon rate of 7.60 per cent per annum. Meanwhile, shares of the company closed trading at Rs 1072.65 apiece, down 1.27 per cent from the previous close on BSE.

19-09-2017 16:14

Tata Chemicals sells shares of Tata Global Beverages

Tata Group entity, Tata Chemicals said that it has sold entire shareholding of 4,31,75,140 equity shares of Tata Global Beverages to Tata Sons through a block deal. “The Company has today, i.e., September 19, 2017, sold 4,31,75,140 Equity Shares of face value of Rs. 1/- each of Tata Global Beverages Limited to Tata Sons Limited at price of Rs. 213.35 per share,” it said in a filing to the Bombay Stock Exchange. The chemical company sold these shares at a price of Rs 213.35 per share (excluding brokerage and STT). Promoter group's shareholding stood at 35.76 per cent stake in Tata Global as of June 2017, including Tata Sons' stake of 23.5 per cent that increased to over 30 per cent post block deal. Meanwhile, shares of Tata Chemicals closed trading at Rs 656.95 apiece, up 2.24 per cent from the previous close on BSE.

19-09-2017 15:55

KPTL raises Rs 100 cr on private placement basis

Kalpataru Power Transmission Ltd said that it has raised Rs 100 crore by issuing Non-Convertible Debentures on private placement basis. “The executive committee of board of directors of the company at its meeting held today has approved issuance of listed, rated, unsecured redeemable taxable non convertible debentures of Rs 100 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds carrying a coupon rate of 8.11 per cent p.a. are proposed to be listed on wholesale debt market segment of BSE Ltd. The debentures having a tenure of 5 years from the deemed date of allotment will mature on 27th September 2022, the filing added. Meanwhile, shares of the company closed trading at Rs 362.50 apiece, up 2.13 per cent from the previous close on BSE.

19-09-2017 15:46

Cadila Healthcare enters into agreement with Pharm Aid

Cadila Healthcare Limited, an innovation-driven global healthcare company has said that it has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid Ltd., headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid Ltd, has been set up by Nacimbio together with Ishvan Pharmaceuticals Ltd., for the localization of innovative vaccine production in Russia. Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme. The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone. Meanwhile, shares of the company were trading at Rs 485.50 apiece, down 0.22 per cent from the previous close at 15:11 hours on BSE.

19-09-2017 15:05

Aarti Drugs Ltd - Press Release

Aarti Drugs Limited has informed the Exchange regarding a press release dated August 21, 2017, titled Press Release for the Quarter ended June, 2017..

21-Aug-2017 04:00 PM

Aarti Drugs Ltd - Press Release / Media Release

Press Release for the Quarter ended June, 2017.

21-Aug-2017 03:55 PM

Aarti Drugs Ltd - Amendments to Memorandum & Articles of Association

Pursuant to Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the shareholders at its Annual General Meeting held on 18th August, 2017 has approved the alteration of Articles of Association of the Company. The existing Article 86(1) is being replaced and it inter-alia contains provision for the following: Shri Prakash M. Patil, Managing Director and Shri Rashesh C. Gogri, Managing Director of the Company shall not be liable to retire by rotation. '.

21-Aug-2017 03:46 PM

Aarti Drugs Ltd - Updates

Aarti Drugs Limited has informed the Exchange regarding ''Pursuant to Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the shareholders at its Annual General Meeting held on 18th August, 2017 has approved the alteration of Articles of Association of the Company. The existing Article 86(1) is being replaced and it inter-alia contains provision for the following:Shri Prakash M. Patil, Managing Director and Shri Rashesh C. Gogri, Managing Director of the Company shall not be liable to retire by rotation. ''.

19-Aug-2017 06:48 PM

Aarti Drugs Ltd - Shareholders meeting

Aarti Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 18, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

19-Aug-2017 06:43 PM

Aarti Drugs Ltd - Press Release / Media Release

Press Release for the Quarter ended June, 2017.

21-Aug-2017 03:55 PM

Aarti Drugs Ltd - Amendments to Memorandum & Articles of Association

Pursuant to Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the shareholders at its Annual General Meeting held on 18th August, 2017 has approved the alteration of Articles of Association of the Company. The existing Article 86(1) is being replaced and it inter-alia contains provision for the following: Shri Prakash M. Patil, Managing Director and Shri Rashesh C. Gogri, Managing Director of the Company shall not be liable to retire by rotation. '.

21-Aug-2017 03:46 PM

Aarti Drugs Ltd - Scrutinizer's Report

Scrutinizer's Report

19-Aug-2017 05:57 PM

Corporate Details

About Management

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1.

Registered Office

Plot Nos. D-277/278, TTC Industrial Area, Turbhe

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.